NCT07570823
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Hemic and Lymphatic Diseases, +5 more
- Locations
-
- Beijing Cancer Hospital Beijing, China
Clinical trial condition
DLBCL - Diffuse Large B Cell Lymphoma
Explore clinical trials studying DLBCL - Diffuse Large B Cell Lymphoma. Study availability and eligibility vary by location and protocol.
46 public trials
27 recruiting studies
DLBCL - Diffuse Large B Cell Lymphoma trial results
Recruiting
Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma.
NCT07739654
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Hemic and Lymphatic Diseases, +11 more
- Locations
-
- Mayo Hospital Lahore, Punjab Province, Pakistan
NCT07749365
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Hemic and Lymphatic Diseases, +6 more
- Locations
-
- The First Affiliated Hospital of Xiamen University Xiamen, Fujian, China
Recruiting
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
NCT07121946
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Follicular Lymphoma ( FL), +18 more
- Locations
-
- City of Hope Duarte, California, United States
- Washington University School of Medicine St Louis, Missouri, United States
- Roswell Park Cancer Institute Buffalo, New York, United States
- Memorial Sloan Kettering Cancer Center - Bergen New York, United States
NCT07680933
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Hemic and Lymphatic Diseases, +5 more
- Locations
-
- The Affiliated Hospital of Xuzhou Medical University Xuzhou, Jiangsu, China
Recruiting
CAR-T Followed by Bispecific Antibodies
NCT04889716
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Hemic and Lymphatic Diseases, +6 more
- Locations
-
- University of Nebraska Medical Center Omaha, Nebraska, United States
- Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States
Recruiting
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
NCT07249905
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, DLBCL - Diffuse Large B Cell Lymphoma, +28 more
- Locations
-
- Epworth HealthCare Richmond, Victoria, Australia
- Linear Clinical Research Nedlands, Western Australia, Australia
NCT07548697
- Conditions
- B-cell Non Hodgkin Lymphoma (NHL), DLBCL - Diffuse Large B Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, +14 more
- Locations
-
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China
Recruiting
SynKIR-310 for Relapsed/Refractory B-NHL
NCT06544265
- Conditions
- Aggressive B-Cell Non-Hodgkin Lymphoma, B Cell Lymphoma, Blood Protein Disorders, +54 more
- Locations
-
- Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute Denver, Colorado, United States
- Winship Cancer Institute of Emory University Atlanta, Georgia, United States
- The University of Kansas Cancer Center Fairway, Kansas, United States
- Rutgers Cancer Institute New Brunswick, New Jersey, United States
NCT06481826
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Hemic and Lymphatic Diseases, +5 more
- Locations
-
- Peking Union Medical College Hospital Beijing, Beijing Municipality, China